4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics, Inc. is a late-stage biotechnology company listed on the NASDAQ under the ticker FDMT. The company develops adeno-associated virus vectors using its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution, with operations in the Netherlands and the United States. Its lead candidate is 4D-150, an intravitreal gene therapy being developed for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, with the aim of enabling sustained anti-VEGF production from the retina over multiple years. The pipeline also includes 4D-710 for cystic fibrosis, 4D-175 for geographic atrophy, and 4D-725 for alpha-1 anti-trypsin deficiency lung disease, each at different development stages. The company also has collaboration and licensing arrangements with Otsuka Pharmaceutical Co., Ltd. Founded in 2013, 4D Molecular Therapeutics is headquartered in Emeryville, California.

Jump directly to the stock analysis sections supported by the latest available data.